V503（ヒトパピローマウイルスワクチン）：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Symptoms 14
4 Vaccination Recommendations and Coverage Rates 16
4.1 Vaccination Recommendations Overview 16
5 Competitive Assessment 18
5.1 Overview 18
5.2 Strategic Competitor Assessment 18
6 Unmet Need and Opportunity 21
6.1 Overview 21
6.2 Protection against Multiple HPV Types 22
6.2.1 Unmet Need 22
6.2.2 Gap Analysis 23
6.2.3 Opportunity 24
6.3 Vaccine Coverage Rates 24
6.3.1 Unmet Need 24
6.3.2 Gap Analysis 25
6.3.3 Opportunity 25
6.4 Perception of Vaccine Safety 26
6.4.1 Unmet Need 26
6.4.2 Gap Analysis 27
6.4.3 Opportunity 27
6.5 Awareness of HPV Vaccination 28
6.5.1 Unmet Need 28
6.5.2 Gap Analysis 28
6.5.3 Opportunity 29
6.6 Affordability of HPV Vaccines 29
6.6.1 Unmet Need 29
6.6.2 Gap Analysis 30
6.6.3 Opportunity 30
6.7 Coverage of HPV Types Prevalent in Certain Populations 31
6.7.1 Unmet Need 31
6.7.2 Gap Analysis 32
6.7.3 Opportunity 32
6.8 Vaccine Compliance Rates 33
6.8.1 Unmet Need 33
6.8.2 Gap Analysis 33
6.8.3 Opportunity 34
6.9 Lifelong Protection from HPV Infection Not Established 34
6.9.1 Unmet Need 34
6.9.2 Gap Analysis 35
6.9.3 Opportunity 35
6.10 Ongoing Need for Cervical Cancer Screening 36
6.10.1 Unmet Need 36
6.10.2 Gap Analysis 36
6.10.3 Opportunity 37
7 Pipeline Assessment 38
7.1 Overview 38
7.2 Promising Vaccines in Clinical Development 39
8 V503 41
8.1 Overview 41
8.2 Immunogenicity 42
8.3 Safety 43
8.4 Dosing and Formulation 44
8.5 Potential Clinical Positioning 44
8.6 Potential Commercial Positioning 45
8.7 Pricing and Reimbursement 45
8.8 SWOT Analysis 46
8.9 Forecast 47
9 Appendix 48
9.1 Bibliography 48
9.2 Abbreviations 57
9.3 Methodology 59
9.4 Forecasting Methodology 59
9.4.1 Vaccine Coverage 60
9.4.2 Vaccine Approval versus Routine Schedule Inclusion 60
9.4.3 General Pricing Assumptions 61
9.4.4 Individual Drug Assumptions 61
9.4.5 Pricing of Pipeline Agents 62
9.5 Physicians and Specialists Included in this Study 63
9.6 About the Author(s) 66
9.6.1 Author(s) 66
9.6.2 Therapy Area Director 66
9.6.3 Global Head of Healthcare 67
9.7 About GlobalData 68
9.8 Disclaimer 68